Incysus Therapeutics, Inc. today announced that William Ho, President and Chief Executive Officer of Incysus will participate in a panel, entitled, “Cell Therapy, Make Room,” during the 2nd Annual Evercore ISI HealthCONx Conference on Wednesday, December 4 at 11:45 a.m. Eastern Time.  The conference will be held at the Four Seasons Hotel Boston, MA.

Link

Incysus Therapeutics, Inc. today announced that data related to the preclinical characterization of its therapeutic agent will be presented during the 24th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology.  Dr. Burt Nabors, the study Principal Investigator and Director of the Neuro-Oncology program for the O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham (UAB) will present the data on Friday, November 22 at the JW Marriott Desert Ridge Hotel.

Link

Incysus Therapeutics, Inc. today announced that the Company will present at the 2019 New York Oncology Investor Conference being held in New York City on November 12th-13th. William Ho, President and Chief Executive Officer of Incysus Therapeutics, will present a company overview on Tuesday, November 12, 2019 at 10:40 a.m. Eastern Time

Link

Incysus Therapeutics, Inc. today announced that the company will present at the 2019 BIO Investor Forum being held in San Francisco, CA on October 22nd.  William Ho, President and Chief Executive Officer of Incysus, will present a company overview.

Link

Incysus Therapeutics, Inc. today announced that the company will present at the 5th Annual CAR-TCR Summit being held September 10-13, 2019 in Boston, MA.  William Ho, CEO is scheduled to participate in a Discovery panel session on Thursday, September 12, 2019, at 12:30 p.m. EDT and Lawrence Lamb, PhD, CSO will present at a scientific symposium in the Translation track at 3:32 p.m. EDT.

Link

Incysus Therapeutics, Inc. today announced that it has been invited to present at the BioCentury 26th Annual NewsMakers in the Biotech Industry Conference on Friday, September 6, 2019, in New York.

Link

Incysus Therapeutics, Inc. today announced the appointment of Peter C. Brandt to its Board of Directors. With his many decades of leadership in the life sciences, including 28 years at Pfizer, Peter brings invaluable expertise that will further strengthen our team at this important time as we anticipate initiating the first clinical trials of our γδ T cell technologies.

Link

Incysus Therapeutics, Inc. today announced the appointment of Rozanna Yaing, as Senior Vice President, Quality and Regulatory Affairs.  Ms. Yaing will be responsible for quality and regulatory affairs across Incysus’ portfolio and will serve on the Company’s Executive Committee.

Link

Incysus Therapeutics, Inc. today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 10,322,145 titled “Drug Resistant Immunotherapy for Treatment of a Cancer.”  The patent covers the treatment of brain cancer with the combination of certain chemotherapies and a γδ T cell genetically modified to confer chemotherapy resistance. The full text of this patent is available from the USPTO website (https://bit.ly/2ZxbxKe).

Link

Incysus Therapeutics, Inc. today announced that William Ho, Chief Executive Officer and co-founder will present and host investor meetings at the Jefferies 2019 Global Healthcare Conference being held in New York, NY on June 4-7.  The presentation is scheduled for Friday, June 7 at 9:00am Eastern Time.  The webcast can be accessed here:  https://bit.ly/ICYSJefco2019

Link

Incysus Therapeutics, Inc. today announced Lawrence S. Lamb, PhD, scientific co-founder and Chief Scientific Officer of Incysus will present at a scientific symposium on Thursday, May 9, 2019 during the Allogeneic Cell Therapies Summit 2019 (ACTS), in Boston, Massachusetts.  The session titled, “Driving the Road to Off-the-Shelf Allogeneic γδ Cell Therapies” will discuss and differentiate Incysus’ development programs in the γδ T cell space.

Link

Incysus Therapeutics, Inc. today announced the appointment of Melissa Beelen, as Vice President, Clinical Operations.  Ms. Beelen will be responsible for strategic leadership and head clinical operations as the company advances its first programs into the clinic.

Link

Incysus Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for the clinical study of a genetically modified γδ T cell in combination with chemotherapy for the treatment of patients with newly-diagnosed glioblastoma (GBM).  This represents the first genetically modified γδ T cell product candidate that the FDA has cleared for a clinical trial.

Link

Incysus Therapeutics, Inc. today announced that Lawrence S. Lamb, PhD, Incysus’ Chief Scientific Officer, will present new preclinical data on Incysus’ drug resistant immunotherapy (DRI) approach during the AACR Annual Meeting.  The poster presentation (abstract # – 2262) will be held on Monday April 1, 2019 during the Combination Immunotherapies I session.

Link

Incysus Therapeutics, Inc. today announced that Lawrence S. Lamb, PhD has joined the company as its Executive Vice President and Chief Scientific Officer.  Dr. Lamb will lead the company’s research and development programs and will be responsible for setting scientific strategy.

Link

Incysus Therapeutics, Inc. today announced the closing of a $10 million Series A round of financing. Proceeds from the financing will be used to expand the management team and support advancement of the Company’s drug-resistant immunotherapy technology in both clinical and pre-clinical programs.  The company expects to initiate its first two Phase 1 clinical programs in the first half of 2019.

Link